Breast Implant ALCL Lawsuits Continue To Mount As New Cases of Cancer Diagnosed

Women continue to be diagnosed with BIA-ALCL and other health problems more than two years after Allergan's Biocell breast implants were recalled.

A steady stream of new breast implant lawsuits continue to be filed against Allergan more than two years after a recall was issued for Biocell textured implants, as women continue to be diagnosed with new cases of a rare cancer linked to the design, which is now commonly referred to as breast implant-associated anaplastic large cell lymphoma (BIA-ALCL).

Allergan Biocell implants were sold for years, featuring a macrotextured surface that has now be linked to an increased risk of cancer that may develop in the tissue surrounding the implant. A massive breast implant recall was issued in July 2019, removing the entire product line from the global market due to concerns about long-term cancer risks as the textured implants remained in place.

Nearly 1,000 product liability lawsuits have been filed by women throughout the federal court system over the past two years, which were consolidated before one federal judge in December 2019, as part of a multidistrict litigation, or MDL. However, new complaints continue to be brought, often involving women diagnosed with the breast implant lymphoma years after the recall.

Learn More About

Breast Implant Lawsuits

Women may face a risk of Anaplastic Large Cell Lymphoma (ALCL) from certain breast implants.

Learn More SEE IF YOU QUALIFY FOR COMPENSATION

Last month, a complaint (PDF) was filed by Janet Nolan, indicating that she was diagnosed with breast implant ALCL in September 2021, alleging that the cancer was caused by one of Allergan’s Natrelle saline-filled breast implants placed in June 2004.

Similarly, another complaint (PDF) was filed on Monday by Meagan Joplin, of Texas, indicating that she was diagnosed with BIA-ALCL in July 2021, after receiving defective implants in May 2016. As a result of the recent cancer diagnosis, the breast implants were explanted in August 2021.

While the size and scope of the breast implant litigation continues to grow, coordinated discovery is being conducted by the parties and a small group of bellwether claims are being prepared for early trial dates to help the parties gauge how juries may respond to certain evidence and testimony that will be repeated throughout the lawsuits.

0 Comments

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Lawyers Propose MDL Trial Dates for Baby Formula NEC Lawsuit Starting in May 2025
Lawyers Propose MDL Trial Dates for Baby Formula NEC Lawsuit Starting in May 2025 (Posted today)

A series of four bellwether claims in the baby formula NEC lawsuit MDL will be ready to go before a federal juries in May 2025, August 2025, November 2025 and February 2026 according to a proposed trial schedule agreed upon by both plaintiffs and defendants.

AngioDynamics Port Catheter Lawsuit MDL Established in Southern District of California
AngioDynamics Port Catheter Lawsuit MDL Established in Southern District of California (Posted yesterday)

U.S. JPML has transferred all AngioDynamics port catheter lawsuits to the U.S. District Court for the Southern District of California, for coordinated discovery and pretrial proceedings as part of a federal MDL (multidistrict litigation).